Cytokinetics (CYTK) Return on Capital Employed (2011 - 2026)
Cytokinetics (CYTK) posted quarterly Return on Capital Employed of 55.68% for Q1 2026, down 747.0% year-over-year from 8.61% in Q1 2025, and down 11.69% quarter-over-quarter from 49.85% in Q4 2025.
Cytokinetics (CYTK) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Return on Capital Employed for 15 consecutive years, with 55.68% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 747.0% year-over-year to 55.68%; the TTM figure through Mar 2026 stood at 55.68% (down 747.0% YoY), while the FY2025 annual figure was 50.57%, up 688.0% from the prior year.
- Return on Capital Employed retreated to 55.68% in Q1 2026 per CYTK's latest filing, from 49.85% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.04% in Q2 2022 and bottomed at 72.99% in Q4 2023.
- Historically, Return on Capital Employed has averaged 47.73% across 5 years, with a median of 48.19% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 4681 bps — and 2024, when it jumped 3435 bps.
- Cytokinetics' Return on Capital Employed stood at 33.74% in 2022, then tumbled by 116 bps to 72.99% in 2023, then jumped by 41 bps to 43.27% in 2024, then declined by 15 bps to 49.85% in 2025, then dropped by 12 bps to 55.68% in 2026.
- Business Quant data shows CYTK's Return on Capital Employed at 55.68% in Q1 2026, 49.85% in Q4 2025, and 48.19% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -49.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.94% |
| Mar 31, 2026 | -55.68% |
| Dec 31, 2025 | -49.85% |
| Sep 30, 2025 | -48.19% |
| Jun 30, 2025 | -49.11% |
| Mar 31, 2025 | -48.22% |
| Dec 31, 2024 | -43.27% |
| Sep 30, 2024 | -38.29% |
| Jun 30, 2024 | -47.60% |
| Mar 31, 2024 | -68.46% |
| Dec 31, 2023 | -72.99% |
| Sep 30, 2023 | -72.64% |
| Jun 30, 2023 | -62.66% |
| Mar 31, 2023 | -42.28% |
| Dec 31, 2022 | -33.74% |
| Sep 30, 2022 | -25.83% |
| Jun 30, 2022 | -24.04% |
| Mar 31, 2022 | -28.59% |
| Dec 31, 2021 | -24.43% |
| Sep 30, 2021 | -32.68% |